This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Abdulrahman R.M., Verloop H., Hoftijzer H., Verburg E., Hovens G.C., Corssmit E.P., Reiners C., Gelderblom H., Pereira A.M., Kapiteijn E., Romijn J.A., Visser T.J., Smit J.W.: Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J. Clin. Endocrinol. Metab., 2010; 95: 3758–3762AbdulrahmanR.M.VerloopH.HoftijzerH.VerburgE.HovensG.C.CorssmitE.P.ReinersC.GelderblomH.PereiraA.M.KapiteijnE.RomijnJ.A.VisserT.J.SmitJ.W.Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination2010953758376210.1210/jc.2009-250720484486Search in Google Scholar
Angell T.E.: Thyroiditis while receiving programmed death ligand 1 (PD-L1) inhibitor therapy for nonthyroid cancers is associated with improved overall survival. Clin. Thyroidol., 2020; 32: 65–68AngellT.E.Thyroiditis while receiving programmed death ligand 1 (PD-L1) inhibitor therapy for nonthyroid cancers is associated with improved overall survival202032656810.1089/ct.2020;32.65-68Search in Google Scholar
Arima H., Iwama S., Inaba H., Ariyasu H., Makita N., Otsuki M., Kageyama K., Imagawa A., Akamizu T.: Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society. Endocr. J., 2019; 66: 581–586ArimaH.IwamaS.InabaH.AriyasuH.MakitaN.OtsukiM.KageyamaK.ImagawaA.AkamizuT.Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society20196658158610.1507/endocrj.EJ19-0163Search in Google Scholar
Baldazzi V., Tassi R., Lapini A., Lunghi A., Garofoli E., Caruso S., Carini M., Mazzanti R.: Sunitinib-induced hyperparathyroidism: A possible mechanism to altered bone homeostasis. Cancer, 2012; 118: 3165–3172BaldazziV.TassiR.LapiniA.LunghiA.GarofoliE.CarusoS.CariniM.MazzantiR.Sunitinib-induced hyperparathyroidism: A possible mechanism to altered bone homeostasis20121183165317210.1002/cncr.26435Search in Google Scholar
Barroso-Sousa R., Barry W.T., Garrido-Castro A.C., Hodi F.S., Min L., Krop I.E., Tolaney S.M.: Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis. JAMA Oncol., 2018; 4: 173–182Barroso-SousaR.BarryW.T.Garrido-CastroA.C.HodiF.S.MinL.KropI.E.TolaneyS.M.Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis2018417318210.1001/jamaoncol.2017.3064Search in Google Scholar
Bjornsti M.A., Houghton P.J: The TOR pathway: A target for cancer therapy. Nat. Rev. Cancer, 2004; 4: 335–348BjornstiM.A.HoughtonP.J.The TOR pathway: A target for cancer therapy2004433534810.1038/nrc1362Search in Google Scholar
Blagosklonny M.V.: Fasting and rapamycin: Diabetes versus benevolent glucose intolerance. Cell Death Dis., 2019; 10: 607BlagosklonnyM.V.Fasting and rapamycin: Diabetes versus benevolent glucose intolerance20191060710.1038/s41419-019-1822-8Search in Google Scholar
Blagosklonny M.V.: Rapamycin for longevity: Opinion article. Aging, 2019; 11: 8048–8067BlagosklonnyM.V.Rapamycin for longevity: Opinion article2019118048806710.18632/aging.102355Search in Google Scholar
Brancatella A., Viola N., Brogioni S., Montanelli L., Sardella C., Vitti P., Marcocci C., Lupi I., Latrofa F.: Graves’ disease induced by immune checkpoint inhibitors: A case report and review of the literature. Eur. Thyroid J., 2019; 8: 192–195BrancatellaA.ViolaN.BrogioniS.MontanelliL.SardellaC.VittiP.MarcocciC.LupiI.LatrofaF.Graves’ disease induced by immune checkpoint inhibitors: A case report and review of the literature2019819219510.1159/000501824Search in Google Scholar
Braun D., Kim T.D., le Coutre P., Köhrle J., Hershman J.M., Schweizer U.: Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport. J. Clin. Endocrinol. Metab., 2012; 97: E100–E105BraunD.KimT.D.le CoutreP.KöhrleJ.HershmanJ.M.SchweizerU.Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport201297E100E10510.1210/jc.2011-1837Search in Google Scholar
Buffier P., Bouillet B., Smati S., Archambeaud F., Cariou B., Verges B.: Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitors. Ann. Endocrinol., 2018; 79: 574–582BuffierP.BouilletB.SmatiS.ArchambeaudF.CariouB.VergesB.Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitors20187957458210.1016/j.ando.2018.07.01130174137Search in Google Scholar
Castinetti F., Albarel F., Archambeaud F., Bertherat J., Bouillet B., Buffier P., Briet C., Cariou B., Caron P., Chabre O., Chanson P., Cortet C., Do Cao C., Drui D., Haissaguerre M. i wsp.: Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions. Ann. Endocrinol., 2018; 79: 591–595CastinettiF.AlbarelF.ArchambeaudF.BertheratJ.BouilletB.BuffierP.BrietC.CariouB.CaronP.ChabreO.ChansonP.CortetC.Do CaoC.DruiD.HaissaguerreM.i wsp.Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions20187959159510.1016/j.ando.2018.07.00530056975Search in Google Scholar
Castinetti F., Borson-Chazot F.: Introduction to expert opinion on endocrine complications of new anticancer therapies. Ann. Endocrinol., 2018; 79: 535–538CastinettiF.Borson-ChazotF.Introduction to expert opinion on endocrine complications of new anticancer therapies20187953553810.1016/j.ando.2018.07.00130056976Search in Google Scholar
Clemons J., Gao D., Naam M., Breaker K., Garfield D., Flaig T.W.: Thyroid dysfunction in patients treated with sunitinib or sorafenib. Clin. Genitourin. Cancer, 2012; 10: 225–231ClemonsJ.GaoD.NaamM.BreakerK.GarfieldD.FlaigT.W.Thyroid dysfunction in patients treated with sunitinib or sorafenib20121022523110.1016/j.clgc.2012.08.002351190823017335Search in Google Scholar
Corsello S.M., Barnabei A., Marchetti P., De Vecchis L., Salvatori R., Torino F.: Endocrine side effects induced by immune checkpoint inhibitors. J. Clin. Endocrinol. Metab., 2013; 98: 1361–1375CorselloS.M.BarnabeiA.MarchettiP.De VecchisL.SalvatoriR.TorinoF.Endocrine side effects induced by immune checkpoint inhibitors2013981361137510.1210/jc.2012-407523471977Search in Google Scholar
Darvin P., Toor S.M., Nair V.S, Elkord E.: Immune checkpoint inhibitors: Recent progress and potential biomarkers. Exp. Mol. Med., 2018; 50: 1–11DarvinP.ToorS.M.NairV.S.ElkordE.Immune checkpoint inhibitors: Recent progress and potential biomarkers20185011110.1038/s12276-018-0191-1629289030546008Search in Google Scholar
de Filette J., Andreescu C.E., Cools F., Bravenboer B., Velkeniers B.: A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm. Metab. Res., 2019; 51: 145–156de FiletteJ.AndreescuC.E.CoolsF.BravenboerB.VelkeniersB.A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors20195114515610.1055/a-0843-336630861560Search in Google Scholar
de Filette J.M., Pen J.J., Decoster L., Vissers T., Bravenboer B., Van der Auwera B.J., Gorus F.K., Roep B.O., Aspeslagh S., Neyns B., Velkeniers B., Kharagjitsingh A.V.: Immune checkpoint inhibitors and type 1 diabetes mellitus: A case report and systematic review. Eur. J. Endocrinol., 2019; 181: 363–374de FiletteJ.M.PenJ.J.DecosterL.VissersT.BravenboerB.Van der AuweraB.J.GorusF.K.RoepB.O.AspeslaghS.NeynsB.VelkeniersB.KharagjitsinghA.V.Immune checkpoint inhibitors and type 1 diabetes mellitus: A case report and systematic review201918136337410.1530/EJE-19-0291670954531330498Search in Google Scholar
Deligiorgi M.V., Panayiotidis M.I., Trafalis D.T.: Parathyroid hormone related protein (PTHrP)-mediated hypercalcemia in malignancy associated with anti-PD-1 immune checkpoint inhibitor treatment and related inflammatory reactions. Int. Immunopharmacol., 2019; 77: 105942DeligiorgiM.V.PanayiotidisM.I.TrafalisD.T.Parathyroid hormone related protein (PTHrP)-mediated hypercalcemia in malignancy associated with anti-PD-1 immune checkpoint inhibitor treatment and related inflammatory reactions20197710594210.1016/j.intimp.2019.10594231699669Search in Google Scholar
Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., Singer S., Janicek M., Fletcher J.A., Silverman S.G., Silberman S.L., Capdeville R., Kiese B. i wsp.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med., 2002; 347: 472–480DemetriG.D.von MehrenM.BlankeC.D.Van den AbbeeleA.D.EisenbergB.RobertsP.J.HeinrichM.C.TuvesonD.A.SingerS.JanicekM.FletcherJ.A.SilvermanS.G.SilbermanS.L.CapdevilleR.KieseB.i wsp.Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors200234747248010.1056/NEJMoa02046112181401Search in Google Scholar
Feldt S., Schüssel K., Quinzler R., Franzmann A., Czeche S., Ludwig W.D., Schulz M.: Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: A cohort study. Eur. J. Cancer, 2012; 48: 974–981FeldtS.SchüsselK.QuinzlerR.FranzmannA.CzecheS.LudwigW.D.SchulzM.Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: A cohort study20124897498110.1016/j.ejca.2012.01.03622382202Search in Google Scholar
Fountas A., Diamantopoulos L.N., Tsatsoulis A.: Tyrosine kinase inhibitors and diabetes: A novel treatment paradigm? Trends Endocrinol. Metab., 2015; 26: 643–656FountasA.DiamantopoulosL.N.TsatsoulisA.Tyrosine kinase inhibitors and diabetes: A novel treatment paradigm?20152664365610.1016/j.tem.2015.09.00326492832Search in Google Scholar
Fraenkel M., Ketzinel-Gilad M., Ariav Y., Pappo O., Karaca M., Castel J., Berthault M.F., Magnan C., Cerasi E., Kaiser N., Leibowitz G.: mTOR inhibition by rapamycin prevents – β cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes, 2008; 57: 945–957FraenkelM.Ketzinel-GiladM.AriavY.PappoO.KaracaM.CastelJ.BerthaultM.F.MagnanC.CerasiE.KaiserN.LeibowitzG.mTOR inhibition by rapamycin prevents – β cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes20085794595710.2337/db07-092218174523Search in Google Scholar
Green M.R., Newton M.D., Fancher K.M.: Off-target effects of BCR-ABL and JAK2 inhibitors. Am. J. Clin. Oncol., 2016; 39: 76–84GreenM.R.NewtonM.D.FancherK.M.Off-target effects of BCR-ABL and JAK2 inhibitors201639768410.1097/COC.000000000000002324351780Search in Google Scholar
Guertin D.A, Sabatini D.M.: Defining the role of mTOR in cancer. Cancer Cell, 2007; 12: 9–22GuertinD.A.SabatiniD.M.Defining the role of mTOR in cancer20071292210.1016/j.ccr.2007.05.00817613433Search in Google Scholar
Gutierrez C., McEvoy C., Munshi L., Stephens R.S., Detsky M.E., Nates J.L., Pastores S.M.: Critical care management of toxicities associated with targeted agents and immunotherapies for cancer. Crit. Care Med., 2020; 48: 10–21GutierrezC.McEvoyC.MunshiL.StephensR.S.DetskyM.E.NatesJ.L.PastoresS.M.Critical care management of toxicities associated with targeted agents and immunotherapies for cancer202048102110.1097/CCM.0000000000004087750509231725440Search in Google Scholar
Hay N., Sonenberg N.: Upstream and downstream of mTOR. Genes Dev., 2004; 18: 1926–1945HayN.SonenbergN.Upstream and downstream of mTOR2004181926194510.1101/gad.121270415314020Search in Google Scholar
Iyer P.C, Cabanillas M.E., Waguespack S.G., Hu M.I., Thosani S., Lavis V.R., Busaidy N.L., Subudhi S.K., Diab A., Dadu R.: Immune-related thyroiditis with immune checkpoint inhibitors. Thyroid, 2018; 28: 1243–1251IyerP.C.CabanillasM.E.WaguespackS.G.HuM.I.ThosaniS.LavisV.R.BusaidyN.L.SubudhiS.K.DiabA.DaduR.Immune-related thyroiditis with immune checkpoint inhibitors2018281243125110.1089/thy.2018.0116615735930132401Search in Google Scholar
Kappers M.H.W., van Esch J.H.M., Smedts F.M.M., de Krijger R.R., Eechoute K., Mathijssen R.H.J., Sleijfer S., Leijten F., Danser A.H.J., van den Meiracker A.H., Visser T.J.: Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. J. Clin. Endocrinol. Metab., 2011; 96: 3087–3094KappersM.H.W.van EschJ.H.M.SmedtsF.M.M.de KrijgerR.R.EechouteK.MathijssenR.H.J.SleijferS.LeijtenF.DanserA.H.J.van den MeirackerA.H.VisserT.J.Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression2011963087309410.1210/jc.2011-117221816788Search in Google Scholar
Kassi E., Angelousi A., Asonitis N., Diamantopoulos P., Anastasopoulou A., Papaxoinis G., Kokkinos M., Giovanopoulos I., Kyriakakis G., Petychaki F., Savelli A., Benopoulou O., Gogas H.: Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma. Cancer Med., 2019; 8: 6585–6594KassiE.AngelousiA.AsonitisN.DiamantopoulosP.AnastasopoulouA.PapaxoinisG.KokkinosM.GiovanopoulosI.KyriakakisG.PetychakiF.SavelliA.BenopoulouO.GogasH.Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma201986585659410.1002/cam4.2533682597431518074Search in Google Scholar
Kitajima K., Takahashi S., Maeda T., Yoshikawa T., Ohno Y., Fujii M., Miyake H., Fujisawa M., Sugimura K.: Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: Comparison with thyroid function. Eur. J. Radiol., 2012; 81: 2060–2065KitajimaK.TakahashiS.MaedaT.YoshikawaT.OhnoY.FujiiM.MiyakeH.FujisawaM.SugimuraK.Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: Comparison with thyroid function2012812060206510.1016/j.ejrad.2011.06.03521724350Search in Google Scholar
Kluczyński Ł., Gilis-Januszewska A., Rogoziński D., Pantofliński J., Hubalewska-Dydejczyk A.: Hypophysitis-new insights into diagnosis and treatment. Endokrynol. Pol., 2019; 70: 260–269KluczyńskiŁ.Gilis-JanuszewskaA.RogozińskiD.PantoflińskiJ.Hubalewska-DydejczykA.Hypophysitis-new insights into diagnosis and treatment20197026026910.5603/EP.a2019.001531290557Search in Google Scholar
Kobayashi T., Iwama S., Yasuda Y., Okada N., Tsunekawa T., Onoue T., Takagi H., Hagiwara D., Ito Y., Morishita Y., Goto M., Suga H., Banno R., Yokota K. i wsp.: Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: A prospective study. J. Endocr. Soc., 2018; 2: 241–251KobayashiT.IwamaS.YasudaY.OkadaN.TsunekawaT.OnoueT.TakagiH.HagiwaraD.ItoY.MorishitaY.GotoM.SugaH.BannoR.YokotaK.i wsp.Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: A prospective study2018224125110.1210/js.2017-00432583652929600292Search in Google Scholar
Kotwal A., Haddox C., Block M., Kudva Y.C.: Immune checkpoint inhibitors: An emerging cause of insulin-dependent diabetes. BMJ Open Diab. Res. Care, 2019; 7: e000591KotwalA.HaddoxC.BlockM.KudvaY.C.Immune checkpoint inhibitors: An emerging cause of insulin-dependent diabetes20197e00059110.1136/bmjdrc-2018-000591639881330899528Search in Google Scholar
Kraig E., Linehan L.A., Liang H., Romo T.Q., Liu Q., Wu Y., Benavides A.D., Curiel T.J., Javors M.A., Musi N., Chiodo L., Koek W., Gelfond J.A.L., Kellogg D.L.Jr.: A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects. Exp. Gerontol., 2018; 105: 53–69KraigE.LinehanL.A.LiangH.RomoT.Q.LiuQ.WuY.BenavidesA.D.CurielT.J.JavorsM.A.MusiN.ChiodoL.KoekW.GelfondJ.A.L.KelloggD.L.Jr.A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects2018105536910.1016/j.exger.2017.12.026586916629408453Search in Google Scholar
Krajewska J., Paliczka-Cieslik E., Jarzab B.: Managing tyrosine kinase inhibitors side effects in thyroid cancer. Expert Rev. Endocrinol. Metab., 2017; 12: 117–127KrajewskaJ.Paliczka-CieslikE.JarzabB.Managing tyrosine kinase inhibitors side effects in thyroid cancer20171211712710.1080/17446651.2017.130052630063430Search in Google Scholar
Król A., Gawlik T., Jarząb B.: Endocrine complications of cancer immunotherapy. Endokrynol. Pol., 2018; 69: 722–733KrólA.GawlikT.JarząbB.Endocrine complications of cancer immunotherapy20186972273310.5603/EP.a2018.007330618030Search in Google Scholar
Kroschinsky F., Stölzel F., von Bonin S., Beutel G., Kochanek M., Kiehl M., Schellongowski P., Intensive Care in Hematological and Oncological Patients (iCHOP) Collaborative Group: New drugs, new toxicities: Severe side effects of modern targeted and immunotherapy of cancer and their management. Crit. Care, 2017; 21: 89KroschinskyF.StölzelF.von BoninS.BeutelG.KochanekM.KiehlM.SchellongowskiP.Intensive Care in Hematological and Oncological Patients (iCHOP) Collaborative GroupNew drugs, new toxicities: Severe side effects of modern targeted and immunotherapy of cancer and their management2017218910.1186/s13054-017-1678-1539160828407743Search in Google Scholar
Kyi C., Postow M.A.: Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett., 2014; 588: 368–376KyiC.PostowM.A.Checkpoint blocking antibodies in cancer immunotherapy201458836837610.1016/j.febslet.2013.10.01524161671Search in Google Scholar
Lanzolla G., Coppelli A., Cosottini M., Del Prato S., Marcocci C., Lupi I.: Immune checkpoint blockade anti-PD-L1 as a trigger for autoimmune polyendocrine syndrome. J. Endocr. Soc., 2019; 3: 496–503LanzollaG.CoppelliA.CosottiniM.Del PratoS.MarcocciC.LupiI.Immune checkpoint blockade anti-PD-L1 as a trigger for autoimmune polyendocrine syndrome2019349650310.1210/js.2018-00366636462430746508Search in Google Scholar
Li J., Wang M., Zhang B., Wu X., Lin T.L., Liu X.F., Zhou Y., Zhang X.H., Xu H., Shen L.J., Zou J., Lu P., Zhang D., Gu W.J., Zhang M.X., Pan J., Cao H., Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor Association: Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors. World J. Gastroenterol., 2018; 24: 5189–5202LiJ.WangM.ZhangB.WuX.LinT.L.LiuX.F.ZhouY.ZhangX.H.XuH.ShenL.J.ZouJ.LuP.ZhangD.GuW.J.ZhangM.X.PanJ.CaoH.Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor AssociationChinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors2018245189520210.3748/wjg.v24.i46.5189629584030581268Search in Google Scholar
Liu S., Kurzrock R.: Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms. Cancer Treat. Rev., 2014; 40: 883–891LiuS.KurzrockR.Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms20144088389110.1016/j.ctrv.2014.05.00324867380Search in Google Scholar
Lu J., Li L., Lan Y., Liang Y., Meng H.: Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic review and meta-analysis. Cancer Med., 2019; 8: 7503–7515LuJ.LiL.LanY.LiangY.MengH.Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic review and meta-analysis201987503751510.1002/cam4.2661691206231679184Search in Google Scholar
Lupu J., Pages C., Laly P., Delyon J., Laloi M., Petit A., Basset-Seguin N., Oueslati I., Zagdanski A.M., Young J., Bouche C., Lebbé C., Gautier J.F.: Transient pituitary ACTH-dependent Cushing syndrome caused by an immune checkpoint inhibitor combination. Melanoma Res., 2017; 27: 649–652LupuJ.PagesC.LalyP.DelyonJ.LaloiM.PetitA.Basset-SeguinN.OueslatiI.ZagdanskiA.M.YoungJ.BoucheC.LebbéC.GautierJ.F.Transient pituitary ACTH-dependent Cushing syndrome caused by an immune checkpoint inhibitor combination20172764965210.1097/CMR.000000000000040529036015Search in Google Scholar
Makita N., Iiri T.: Tyrosine kinase inhibitor-induced thyroid disorders: A review and hypothesis. Thyroid, 2013; 23: 151–159MakitaN.IiriT.Tyrosine kinase inhibitor-induced thyroid disorders: A review and hypothesis20132315115910.1089/thy.2012.045623398161Search in Google Scholar
Makita N., Miyakawa M., Fujita T., Iiri T.: Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid, 2010; 20: 323–326MakitaN.MiyakawaM.FujitaT.IiriT.Sunitinib induces hypothyroidism with a markedly reduced vascularity20102032332610.1089/thy.2009.041420187785Search in Google Scholar
Mannavola D., Coco P., Vannucchi G., Bertuelli R., Carletto M., Casali P.G., Beck-Peccoz P., Fugazzola L.: A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J. Clin. Endocrinol. Metab., 2007; 92: 3531–3534MannavolaD.CocoP.VannucchiG.BertuelliR.CarlettoM.CasaliP.G.Beck-PeccozP.FugazzolaL.A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake2007923531353410.1210/jc.2007-058617595247Search in Google Scholar
Marcq E., Waele J.D., Audenaerde J.V., Lion E., Santermans E., Hens N., Pauwels P., van Meerbeeck J.P., Smits E.L.J.: Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients. Oncotarget, 2017; 8: 89722–89735MarcqE.WaeleJ.D.AudenaerdeJ.V.LionE.SantermansE.HensN.PauwelsP.van MeerbeeckJ.P.SmitsE.L.J.Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients20178897228973510.18632/oncotarget.21113568570429163783Search in Google Scholar
Martins F., de Oliveira M.A., Wang Q., Sonis S., Gallottini M., George S., Treister N.: A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol., 2013; 49: 293–298MartinsF.de OliveiraM.A.WangQ.SonisS.GallottiniM.GeorgeS.TreisterN.A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients20134929329810.1016/j.oraloncology.2012.11.00823312237Search in Google Scholar
Matrana M.R., Duran C., Shetty A., Xiao L., Atkinson B.J., Corn P., Pagliaro L.C., Millikan R.E., Charnsangave C., Jonasch E., Tannir N.M.: Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur. J. Cancer, 2013; 49: 3169–3175MatranaM.R.DuranC.ShettyA.XiaoL.AtkinsonB.J.CornP.PagliaroL.C.MillikanR.E.CharnsangaveC.JonaschE.TannirN.M.Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies2013493169317510.1016/j.ejca.2013.06.003388215623810246Search in Google Scholar
Min L., Vaidya A., Becker C.: Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur. J. Endocrinol., 2011; 164: 303–307MinL.VaidyaA.BeckerC.Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy201116430330710.1530/EJE-10-0833408062921088057Search in Google Scholar
Neumann D., Korzeniowska K., Jankowski J., Jabłecka A.: Kardiotoksyczność leczenia przeciwnowotworowego. Chor. Serca Naczyń, 2016; 13: 434–444NeumannD.KorzeniowskaK.JankowskiJ.JabłeckaA.Kardiotoksyczność leczenia przeciwnowotworowego201613434444Search in Google Scholar
Nurgali K., Jagoe R.T., Abalo R.: Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae? Front Pharmacol., 2018; 9: 245NurgaliK.JagoeR.T.AbaloR.Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae?2018924510.3389/978-2-88945-482-2Search in Google Scholar
Ohba K., Takayama T., Matsunaga H., Matsushita A., Sasaki S., Oki Y., Ozono S., Nakamura H.: Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib. Thyroid, 2013; 23: 443–448OhbaK.TakayamaT.MatsunagaH.MatsushitaA.SasakiS.OkiY.OzonoS.NakamuraH.Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib20132344344810.1089/thy.2012.037823157669Search in Google Scholar
Pal S.K., Miller M.J., Agarwal N., Chang S.M., Chavez-MacGregor M., Cohen E., Cole S., Dale W., Magid Diefenbach C.S., Disis M.L., Dreicer R., Graham D.L., Henry N.L., Jones J., Keedy V. i wsp.: Clinical cancer advances 2019: Annual report on progress against cancer from the American Society of Clinical Oncology. J. Clin. Oncol., 2019; 37: 834–849PalS.K.MillerM.J.AgarwalN.ChangS.M.Chavez-MacGregorM.CohenE.ColeS.DaleW.Magid DiefenbachC.S.DisisM.L.DreicerR.GrahamD.L.HenryN.L.JonesJ.KeedyV.i wsp.Clinical cancer advances 2019: Annual report on progress against cancer from the American Society of Clinical Oncology20193783484910.1200/JCO.18.0203730702028Search in Google Scholar
Paul M.K., Mukhopadhyay A.K.: Tyrosine kinase – Role and significance in cancer. Int. J. Med. Sci., 2004; 1: 101–115PaulM.K.MukhopadhyayA.K.Tyrosine kinase – Role and significance in cancer2004110111510.7150/ijms.1.101107471815912202Search in Google Scholar
Piranavan P., Li Y., Brown E., Kemp E.H., Trivedi N.: Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies. J. Clin. Endocrinol. Metab., 2019; 104: 550–556PiranavanP.LiY.BrownE.KempE.H.TrivediN.Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies201910455055610.1210/jc.2018-0115130252069Search in Google Scholar
Płużański A., Piórek A.: Side effects of tyrosine kinase inhibitors — management guidelines. Oncol. Clin. Pract., 2016; 12: 113–118PłużańskiA.PiórekA.Side effects of tyrosine kinase inhibitors — management guidelines201612113118Search in Google Scholar
Prete A., Salvatori R.: Hypophysitis. https://www.ncbi.nlm.nih.gov/books/NBK519842 (15.08.2018)PreteA.SalvatoriR.https://www.ncbi.nlm.nih.gov/books/NBK519842 (15.08.2018)Search in Google Scholar
Rini B.I., Tamaskar I., Shaheen P., Salas R., Garcia J., Wood L., Reddy S., Dreicer R., Bukowski R.M.: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J. Nat. Cancer Inst., 2007; 99: 81–83RiniB.I.TamaskarI.ShaheenP.SalasR.GarciaJ.WoodL.ReddyS.DreicerR.BukowskiR.M.Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib200799818310.1093/jnci/djk00817202116Search in Google Scholar
Sagiv O., Kandl T.J, Thakar S.D., Thuro B.A, Busaidy N.L., Cabanillas M., Jimenez C., Dadu R., Graham P.H., Debnam J.M., Esmaeli B.: Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor therapy in cancer patients. Ophthalmic Plast. Reconstr. Surg., 2019; 35: 50–52SagivO.KandlT.J.ThakarS.D.ThuroB.A.BusaidyN.L.CabanillasM.JimenezC.DaduR.GrahamP.H.DebnamJ.M.EsmaeliB.Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor therapy in cancer patients201935505210.1097/IOP.000000000000116129927883Search in Google Scholar
Santoni M., Conti A., Massari F., Di Nunno V., Faloppi L., Galizia E., Morbiducci J., Piva F., Buti S., Iacovelli R., Ferretti B., Cimadamore A., Scarpelli M., Lopez-Beltran A., Cheng L., Battelli N., Montironi R.: Targeted therapy for solid tumors and risk of hypertension: A meta-analysis of 68077 patients from 93 phase III studies. Exp. Rev. Cardiovasc. Ther., 2019; 17: 917–927SantoniM.ContiA.MassariF.Di NunnoV.FaloppiL.GaliziaE.MorbiducciJ.PivaF.ButiS.IacovelliR.FerrettiB.CimadamoreA.ScarpelliM.Lopez-BeltranA.ChengL.BattelliN.MontironiR.Targeted therapy for solid tumors and risk of hypertension: A meta-analysis of 68077 patients from 93 phase III studies20191791792710.1080/14779072.2019.170462631829045Search in Google Scholar
Shu M., Zai X., Zhang B., Wang R., Lin Z.: Hypothyroidism side effect in patients treated with sunitinib or sorafenib: Clinical and structural analyses. PLoS One, 2016; 11: e0147048ShuM.ZaiX.ZhangB.WangR.LinZ.Hypothyroidism side effect in patients treated with sunitinib or sorafenib: Clinical and structural analyses201611e014704810.1371/journal.pone.0147048471844826784451Search in Google Scholar
Sivendran S., Agarwal N., Gartrell B., Ying J., Boucher K.M., Choueiri T.K., Sonpavde G., Oh W.K., Galsky M.D.: Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat. Rev., 2014; 40: 190–196SivendranS.AgarwalN.GartrellB.YingJ.BoucherK.M.ChoueiriT.K.SonpavdeG.OhW.K.GalskyM.D.Metabolic complications with the use of mTOR inhibitors for cancer therapy20144019019610.1016/j.ctrv.2013.04.005474448623684373Search in Google Scholar
Sobańska K., Szałek E., Kamińska A., Grześkowiak E.: Inhibitory kinaz tyrozynowych w terapii przeciwnowotworowej. Farm. Współ., 2011; 4: 185–190SobańskaK.SzałekE.KamińskaA.GrześkowiakE.Inhibitory kinaz tyrozynowych w terapii przeciwnowotworowej20114185190Search in Google Scholar
Sosa A., Lopez Cadena E., Simon Olive C., Karachaliou N., Rosell R.: Clinical assessment of immune-related adverse events. Ther. Adv. Med. Oncol., 2018; 10: 1758835918764628SosaA.Lopez CadenaE.Simon OliveC.KarachaliouN.RosellR.Clinical assessment of immune-related adverse events201810175883591876462810.1177/1758835918764628588203929623110Search in Google Scholar
Tamaskar I., Bukowski R., Elson P., Ioachimescu A.G., Wood L., Dreicer R., Mekhail T., Garcia J., Rini B.I.: Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann. Oncol., 2008; 19: 265–268TamaskarI.BukowskiR.ElsonP.IoachimescuA.G.WoodL.DreicerR.MekhailT.GarciaJ.RiniB.I.Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib20081926526810.1093/annonc/mdm48317962201Search in Google Scholar
Tan M.H., Iyengar R., Mizokami-Stout K., Yentz S., MacEachern M.P., Shen L.Y., Redman B., Gianchandani R.: Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: A scoping review of case reports. Clin. Diabet. Endocrinol., 2019; 5: 1TanM.H.IyengarR.Mizokami-StoutK.YentzS.MacEachernM.P.ShenL.Y.RedmanB.GianchandaniR.Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: A scoping review of case reports20195110.1186/s40842-018-0073-4634325530693099Search in Google Scholar
Torino F., Barnabei A., Paragliola R.M., Marchetti P., Salvatori R., Corsello S.M.: Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur. J. Endocrinol., 2013; 169: R153–R164TorinoF.BarnabeiA.ParagliolaR.M.MarchettiP.SalvatoriR.CorselloS.M.Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses2013169R153R16410.1530/EJE-13-043424001893Search in Google Scholar
Verloop H., Smit J.W., Dekkers O.M.: Sorafenib therapy decreases the clearance of thyrotropin. Eur. J. Endocrinol., 2013; 168: 163–167VerloopH.SmitJ.W.DekkersO.M.Sorafenib therapy decreases the clearance of thyrotropin201316816316710.1530/EJE-12-082823125304Search in Google Scholar
Veroux M., Tallarita T., Corona D., Sinagra N., Giaquinta A., Zerbo D., Guerrieri C., D’Assoro A., Cimino S., Veroux P.: Conversion to sirolimus therapy in kidney transplant recipients with new onset diabetes mellitus after transplantation. Clin. Dev. Immunol., 2013; 2013: 496974VerouxM.TallaritaT.CoronaD.SinagraN.GiaquintaA.ZerboD.GuerrieriC.D’AssoroA.CiminoS.VerouxP.Conversion to sirolimus therapy in kidney transplant recipients with new onset diabetes mellitus after transplantation2013201349697410.1155/2013/496974367152623762090Search in Google Scholar
Walko C.M., Aubert R.E., La-Beck N.M., Clore G., Herrera V., Kourlas H., Epstein R.S., McLeod H.L.: Pharmacoepidemiology of clinically relevant hypothyroidism and hypertension from sunitinib and sorafenib. Oncologist, 2017; 22: 208–212WalkoC.M.AubertR.E.La-BeckN.M.CloreG.HerreraV.KourlasH.EpsteinR.S.McLeodH.L.Pharmacoepidemiology of clinically relevant hypothyroidism and hypertension from sunitinib and sorafenib20172220821210.1634/theoncologist.2016-0233533071028167571Search in Google Scholar
Wang D.Y., Salem J.E., Cohen J.V., Chandra S., Menzer C., Ye F., Zhao S., Das S., Beckermann K.E., Ha L., Rathmell W.K., Ancell K.K., Balko J.M., Bowman C., Davis E.J. i wsp.: Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncol., 2018; 4: 1721–1728WangD.Y.SalemJ.E.CohenJ.V.ChandraS.MenzerC.YeF.ZhaoS.DasS.BeckermannK.E.HaL.RathmellW.K.AncellK.K.BalkoJ.M.BowmanC.DavisE.J.i wsp.Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis201841721172810.1001/jamaoncol.2018.3923644071230242316Search in Google Scholar
Wong E., Rosen L.S., Mulay M., Vanvugt A., Dinolfo M., Tomoda C., Sugawara M., Hershman J.M.: Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid, 2007; 17: 351–355WongE.RosenL.S.MulayM.VanvugtA.DinolfoM.TomodaC.SugawaraM.HershmanJ.M.Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity20071735135510.1089/thy.2006.030817465866Search in Google Scholar
Yajima K., Akise Y.: A case report of Graves’ disease induced by the anti-human programmed cell death-1 monoclonal antibody pembrolizumab in a bladder cancer patient. Case Rep. Endocrinol., 2019; 2019: 2314032YajimaK.AkiseY.A case report of Graves’ disease induced by the anti-human programmed cell death-1 monoclonal antibody pembrolizumab in a bladder cancer patient20192019231403210.1155/2019/2314032685423431772785Search in Google Scholar
Yang J.C., Reguart N., Barinoff J., Köhler J., Uttenreuther-Fischer M., Stammberger U., O’Brien D., Wolf J., Cohen E.E.: Diarrhea associated with afatinib: An oral ErbB family blocker. Expert Rev. Anticancer Ther., 2013; 13: 729–736YangJ.C.ReguartN.BarinoffJ.KöhlerJ.Uttenreuther-FischerM.StammbergerU.O’BrienD.WolfJ.CohenE.E.Diarrhea associated with afatinib: An oral ErbB family blocker20131372973610.1586/era.13.3123506556Search in Google Scholar
Zhao C., Tella S.H., Del Rivero J., Kommalapati A., Ebenuwa I., Gulley J., Strauss J., Brownell I.: Anti-PD-L1 treatment induced central diabetes insipidus. J. Clin. Endocrinol. Metab., 2018; 103: 365–369ZhaoC.TellaS.H.Del RiveroJ.KommalapatiA.EbenuwaI.GulleyJ.StraussJ.BrownellI.Anti-PD-L1 treatment induced central diabetes insipidus201810336536910.1210/jc.2017-01905580082629220526Search in Google Scholar